CASE REPORT s Systemic sarcoidosis induced etanercept Brazilian case report Sarcoidose sistêmica induzida por etanercepte primeiro relato caso brasileiro 197 Natasha Unterstell1 Pérola Peres da Fonseca e Castro1 Aline Lopes Bressan2 Alexandre Carlos Gripp3 Laura Araújo Serpa1 DOI httpdxdoiorg101590abd1806484120132588 Abstract The antagonists tumor necrosis factor alpha TNFα increasingly treatment inflammatory autoimmune diseases Several adverse effects drugs reported including paradoxical development sarcoidosis especially use etanercept We present Brazilian case report systemic sarcoidosis induced etanercept literature review Keywords Diagnosis Granuloma Sarcoidosis Tumor necrosis factoralpha Resumo Os medicamentos antagonistas fator necrose tumoral alfa TNFα estão sendo cada vez mais uti lizados tratamento doenças inflamatórias e autoimunes Efeitos adversos desses medicamentos vem sendo relatados incluindo o desenvolvimento paradoxal sarcoidose principalmente com o uso etanercepte Apresentamos o primeiro relato caso brasileiro sarcoidose sistêmica induzida por etanercepte e uma revi são da literatura Palavraschave Diagnóstico Fator necrose tumoral alfa Granuloma Sarcoidose BACKGROUND Sarcoidosis multisystem disease unknown etiology characterized formation noncaseating granulomas especially lungs lymphnodes eyes skin 1 Tumor necrosis factor antagonists antiTNF treatment cases sarcoidosis secondary drugs detected18 We report case female patient rheumatoid arthritis present ing systemic sarcoidosis 6 months treat ment etanercept CASE REPORT A yearold female patient Caucasian born Rio Janeiro diagnosed rheumatoid arthritis 10 years ago She started treatment weekly etanercept 50 mg subcutaneously year ago poor therapeutic response methotrexate sulphasalazine corticoids Prior starting immunobiologic therapy patient screened thoracic radiographies PPD HIV hepatitis serologic tests normal results After 6 months treatment etanercept infiltrated erythematous lesions appeared surround ing scar posterior region right thigh right gluteal area followed emergence painful erythematous nodules lower limbs increase volume neck Figures 1 2 Our patient denied fever weight loss dyspnea At point thoracic cervical computerized tomogra phy scans performed showing pulmonary peri hilar lymphadenomegaly bilateral augmentation parotids lymphadenomegaly respectively Figure 3 Histopathological examination right thigh skin lesion demonstrated presence non caseating granulomas formed histiocytes giant cells dermis hypodermis Figures 4 5 Received 05032013 Approved Advisory Board accepted publication 02042013 Work performed Pedro Ernesto University Hospital Rio Janeiro State University HUPEUERJ Rio Janeiro RJ Brazil Conflict None Financial Support None 1 MD resident Dermatology Program Pedro Ernesto University Hospital Rio Janeiro State University HUPEUERJ Rio Janeiro RJ Brazil 2 MD dermatologist Attendant dermatology ward immunotherapy clinic Pedro Ernesto University Hospital Rio Janeiro State University HUPEUERJ Rio Janeiro RJ Brazil 3 MD MSc dermatology Chief dermatology ward immunotherapy clinic Pedro Ernesto University Hospital Rio Janeiro State University HUPEUERJ Rio Janeiro RJ Brazil 2013 Anais Brasileiros Dermatologia An Bras Dermatol 2013886 Suppl 11979 198 Unterstell N Bressan AL Serpa LA Castro PPF Gripp AC FIGURE 1 Erythematous infiltrated lesions surrounding cicatricial area posterior region right thigh FIGURE 4 Histopathological exam 100x zoom right thigh lesion showing welldelimitated noncaseating granulomas dermis hypodermis FIGURE 2 Erythema nodosum lower limbs FIGURE 3 Thoracic CT scan showing perihilar pulmonary lymphadenomegaly An Bras Dermatol 2013886 Suppl 11979 FIGURE 5 Histopathological exam 1000x zoom noncaseating gra nuloma formed histiocytes giant cells Skin cultures mycobacteria fungi nega tive angiotensin converting enzyme levels 61 UL reference value 60 UL Etanercept suspended diagnosis sarcoidosis treatment prednisone 30 mgday po initiated resulting improve ment skin cervical pulmonary lesions approximately 30 days The dose prednisone gradually reduced 3 months relapse symptoms observed 6 months followup DISCUSSION The exact etiology sarcoidosis remains unknown It believed exacerbated immune response occur antigenic stimuli infectious environmental agents autoantigens1 Systemic sarcoidosis induced etanercept Brazilian case report 199 Recent studies demonstrated TNF α crucial role forming inflammatory granuloma regulating adhesion molecules recruiting cells activating lymphocytes9 Th1 response pattern The formation granuloma requires cel lular involving type macrophages T CD4 activated lymphocytes Interleukin1b gammainterferon important promoters initial phases granuloma development TNF α hand critical phases granulomatous process10 Tumor necrosis factor antagonists antiTNF treat sarcoidosis theory block cytokines action123 However para doxically cases sarcoidosis induced medications reported8 This perplex ing mechanism clear believed drugs inhibit signaling pathways TNF α ensuing escape routes28 In review published May 2012 Cathcart et al6 34 cases sarcoidosis induced TNF α antagonists described medical literature Twentyone 617 occurred use etanercept 9 264 infliximab 4 117 adalimumab In study mean time appearance granulo mas 22 months start medications6 After literature review 48 case reports sarcoidosis induced TNF α antagonists Thirty 6458 followed etanercept 9 1875 occurred infliximab 8 1666 adali mumab Most patients pulmonary andor lym phnode involvement 8 cases cutaneous mani festations mainly erythema nodosum610 Despite antiTNF drugs having abili ty block proinflammatory cytokine TNFα possess marked differences structures pharmacokinetics pharmacodynam ics attributes explains diversity observed clinical efficacy adverse events including triggering granulomatous lesions7 The inhibition TNF α etanercept complete drug connects sol uble TNF receptor transmembrane receptor occurs infliximab adalimumab Partial neutralization TNF α etanercept permits redistribution cytokine areas lower concentration lungs This explain stronger association granulomatous reactions use etanercept810 The treatment cases sus pension antiTNF agent cases reported introduction corticoids The mean time recovery symptoms interrup tion drug 52 months6 Considering drugs increasingly dermatology remain alert pos sibility sarcoidosis especially respiratory symp toms erythema nodosum andor granulomatous cutaneous eruptions ariseq MAILING ADDRESS Natasha Unterstell Av Vinte e oito setembro 70 Vila Isabel 20551030 Rio Janeiro RJ Brazil Email natasha_unterstellyahoocombr 1 2 3 4 5 6 7 8 9 10 REFE REN CES Daldon PEC Arruda LHF Noninfectious granulomas sarcoidosis An Bras Dermatol 20078255971 Aguiar M Marçal N Mendes AC Bugalho Almeida A Infliximab treating sar coidosis patients Portuguese experience Rev Port Pneumol 2011178593 Hostettler KE Studler U Tamm M Brutsche MH Longterm treatment infliximab patients sarcoidosis Respiration 2012 8321824 Gifre L RuizEsquide V Xaubet A GómezPuerta JA Hernández MV Sanmartí R Lung sarcoidosis induced TNF antagonists rheumatoid arthritis case presen tation literature review Arch Bronconeumol 20114720812 Fok KC Ng WW Henderson CJ Connor SJ Cutaneous sarcoidosis patient ulcerative colitis infliximab J Crohns Colitis 2012670812 Cathcart S Sami N Elewski B Sarcoidosis adverse effect tumor necrosis factor inhibitors J Drugs Dermatol 20121160912 Lamrock E Brown P Development cutaneous sarcoidosis treatment tumor necrosis alpha factor antagonists Australas J Dermatol 201253e8790 Massara A Cavazzini L La Corte R Trotta F Sarcoidosis appearing antitumor necrosis factor alpha therapy new class effect paradoxical phenomenon Two case reports literature review Semin Arthritis Rheum 2010393139 Lukacs NW Chensue SW Strieter RM Warmington K Kunkel SL Inflammatory gra nuloma formation mediated TNFalphainducible intercellular adhesion molecu le1 J Immunol 199415258839 Vigne C Tebib JG Pacheco Y Coury F Sarcoidosis An underestimated poten tially severe effect antiTNFalpha therapy Joint Bone Spine 2013801047 How cite article Unterstell N Bressan AL Serpa LA Castro PPF Gripp AC Systemic sarcoidosis induced etanercept Brazilian case report An Bras Dermatol 2013886 Suppl 1S1979 An Bras Dermatol 2013886 Suppl 11979